Italy· 042658029
TRESIBA*FLEXTOUCH SC 5 penne preriemp 3 ml 100 U/ml
A insulin degludec product containing insulina degludec, registered in Italy by NOVO NORDISK A/S, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Insulin degludec is registered in 14 of 19 countries.
Countries holding a registration under ATC A10AE06 (insulin degludec), each read from that country’s own register.
- This record: Italy
- 9 of them publish a price we can compare per daily dose
Insulin degludec · ATC A10AE06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
- Active substance
- Insulina degludec
- Manufacturer
- NOVO NORDISK A/S
- Country
- Italy (IT)
- ATC code
- A10AE06
- ATC class
- Insulin degludec
- Defined daily dose
- 40 E, P
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic042658029TRESIBA*FLEXTOUCH SC 5 penne preriemp 3 ml 100 U/mlEUR 137.08
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
431 interactions on record for insulin degludec.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Insulin degludec · interactions on record
431 records
- 15 severe
- 366 moderate
- 50 minor
Most severe, free to view
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- PrednisoloneA07EA01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Insulin degludec in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTRESIBANovo Nordisk A/S, Bagsvaerd
- United StatesInsulin DegludecNovo Nordisk Pharma, Inc.
- BelgiumRyzodeg 100 U/mlNovo Nordisk
- United KingdomTresiba FlexTouch 100units/ml solution for injection 3ml pre-filled pensNovo Nordisk Ltd
- FinlandTresibaOrifarm Oy
- SpainTRESIBA 100 UNIDADES/ML FLEXTOUCH SOLUCION INYECTABLE EN PLUMA PRECARGADANovo Nordisk A/S
- SwedenTresiba FlexPen 100 enheter/ml Injektionsvätska, lösning i förfylld injektionspennaNovo Nordisk A/S
- CanadaTRESIBANOVO NORDISK CANADA INC
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Tresiba Flexpen, Tresiba Flextouch
- Norway · Tresiba, Tresiba Flexpen
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5edcd8a8-5bb8-4156-8cc9-b7a66abb0514 GET /v1/drugs/5edcd8a8-5bb8-4156-8cc9-b7a66abb0514?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 137.08,
"source": "aifa",
"currency": "EUR",
"strength": "INSULINA DEGLUDEC 300U 3ML 5 UNITA' USO PARENTERALE",
"substance": "Insulina degludec",
"equivalence_group": "N3B",
"transparency_flag": null
}See everything about insulin degludec.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.